These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 32217639)

  • 1. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Jühling F; Hamdane N; Crouchet E; Li S; El Saghire H; Mukherji A; Fujiwara N; Oudot MA; Thumann C; Saviano A; Roca Suarez AA; Goto K; Masia R; Sojoodi M; Arora G; Aikata H; Ono A; Tabrizian P; Schwartz M; Polyak SJ; Davidson I; Schmidl C; Bock C; Schuster C; Chayama K; Pessaux P; Tanabe KK; Hoshida Y; Zeisel MB; Duong FH; Fuchs BC; Baumert TF
    Gut; 2021 Jan; 70(1):157-169. PubMed ID: 32217639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma.
    Dechassa ML; Tryndyak V; de Conti A; Xiao W; Beland FA; Pogribny IP
    Mol Carcinog; 2018 Aug; 57(8):978-987. PubMed ID: 29603380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.
    Younossi Z; Stepanova M; Ong JP; Jacobson IM; Bugianesi E; Duseja A; Eguchi Y; Wong VW; Negro F; Yilmaz Y; Romero-Gomez M; George J; Ahmed A; Wong R; Younossi I; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):748-755.e3. PubMed ID: 29908364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
    Febbraio MA; Reibe S; Shalapour S; Ooi GJ; Watt MJ; Karin M
    Cell Metab; 2019 Jan; 29(1):18-26. PubMed ID: 30449681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
    J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylase HDAC8 Promotes Insulin Resistance and β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
    Tian Y; Wong VW; Wong GL; Yang W; Sun H; Shen J; Tong JH; Go MY; Cheung YS; Lai PB; Zhou M; Xu G; Huang TH; Yu J; To KF; Cheng AS; Chan HL
    Cancer Res; 2015 Nov; 75(22):4803-16. PubMed ID: 26383163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
    Pinyopornpanish K; Al-Yaman W; Butler RS; Carey W; McCullough A; Romero-Marrero C
    Am J Gastroenterol; 2021 Nov; 116(11):2258-2269. PubMed ID: 34212895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
    Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
    J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
    Takaki Y; Saito Y; Takasugi A; Toshimitsu K; Yamada S; Muramatsu T; Kimura M; Sugiyama K; Suzuki H; Arai E; Ojima H; Kanai Y; Saito H
    Cancer Sci; 2014 Oct; 105(10):1254-60. PubMed ID: 25117675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
    Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
    Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
    [No Abstract]   [Full Text] [Related]  

  • 17. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
    Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
    Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis Is Associated with Histone H4 lysine 16 Deacetylation.
    de Conti A; Dreval K; Tryndyak V; Orisakwe OE; Ross SA; Beland FA; Pogribny IP
    Mol Cancer Res; 2017 Sep; 15(9):1163-1172. PubMed ID: 28512251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.
    Lequoy M; Gigante E; Couty JP; Desbois-Mouthon C
    Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32112699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.